CCN(C(C)C)C(C)C.[C:10]1([CH3:24])[CH:15]=[CH:14][CH:13]=[C:12]([N:16]2[CH:20]=[C:19]([C:21]([OH:23])=O)[N:18]=[N:17]2)[CH:11]=1.CC1C=C(C=CC=1)N.C1C=CC2N(O)N=NC=2C=1.CCN=C=NCCCN(C)C.[NH2:54][CH2:55][C:56]([N:58]1[CH2:63][CH2:62][CH:61]([O:64][C:65]2[CH:70]=[C:69]([F:71])[CH:68]=[CH:67][C:66]=2[Cl:72])[CH2:60][CH2:59]1)=[O:57]>CN(C=O)C.O>[Cl:72][C:66]1[CH:67]=[CH:68][C:69]([F:71])=[CH:70][C:65]=1[O:64][CH:61]1[CH2:62][CH2:63][N:58]([C:56](=[O:57])[CH2:55][NH:54][C:21]([C:19]2[N:18]=[N:17][N:16]([C:12]3[CH:11]=[C:10]([CH3:24])[CH:15]=[CH:14][CH:13]=3)[CH:20]=2)=[O:23])[CH2:59][CH2:60]1DIPEA (171 mg, 1.32 mmol) was added to a stirred solution of 1-m-tolyl-1H-[1,2,3]triazole-4-carboxylic acid (60 mg, 0.29 mmol) (prepared by the method used for the synthesis of Intermediate 64, starting from 3-methylaniline) in DMF (5 mL) followed by HOBt (44 mg, 0.32 mmol) and EDCI (141 mg, 0.73 mmol). After 2 minutes of stirring, 2-amino-1-[4-(2-chloro-5-fluoro-phenoxy)-piperidin-1-yl]-ethanone (105 mg, 0.32 mmol) was added and the resulting mixture was stirred at ambient temperature overnight. Cold water was then added and the precipitate was collected The solid obtained was purified by recrystallisation from a solvent system EtOAc:hexane:MeOH (2:8:0.2) to afford 103 mg (74.1% Yield) of 1-m-tolyl-1H-[1,2,3]triazole-4-carboxylic acid {2-[4-(2-chloro-5-fluoro-phenoxy)-piperidin-1-yl]-2-oxo-ethyl}-amide. LC/MS [M+H]+: 472, 96.02%. 1H NMR (300 MHz, DMSO-d6): δ 8.5 (t, 1H), 7.86 (s, 1H), 7.8 (d, 1H), 7.54-7.44 (m, 2H), 7.38-7.24 (m, 4H), 6.88 (t, 1H), 4.9 (m, 1H), 4.3 (d, 2H), 3.8 (m, 2H), 3.5 (s, 2H), 2.4 (s, 3H), 2.1 (d, 2H), 1.8 (d, 2H).
Wird geladen…